Effect of Long Term Consumption of Infant Formulas With Bifidobacteria (B) and S. Thermophilus (St) on Stool Patterns and Diaper Rash in Infants

Saavedra, José M.; Abi-Hanna, Adel; Moore, Nancy; Yolken, Robert

doi:10.1097/00005176-199810000-00102

Cited by 17 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Supplementation with BB-12 has shown to alleviate clinical symptoms of atopic dermatitis in children (Isolauri et al, 2000) and to increase mucosal immunoglobulin A level (Fukushima et al, 1998). Previously supplementation with BB-12 either alone or in combination with other probiotics, was found to change the ratio between lactic acid bacteria and enterobactericeae in favor of the former (Langhendries et al, 1995;Fukushima et al, 1997Fukushima et al, , 1998Laake et al, 1999;Kirjavainen et al, 2002), and the bowel habits in children as well as in elderly seem to be changed towards a more desirable pattern with softer and more bowel movements (Alm et al, 1993;Saavedra et al, 1998). Concerning the effect on blood lipids in vitro BB-12 showed the ability to deconjugate bile salt and thereby remove cholesterol from a culture medium (Klaver and van der Meer, 1993).…”

Section: Introductionmentioning

confidence: 99%

Dose–response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults

Larsen

Nielsen²,

Kæstel³

et al. 2006

Eur J Clin Nutr

109

View full text Add to dashboard Cite

Objective: This study was performed to investigate the dose-response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 10 10 CFU/day probiotic and placebo group. Design: The study was designed as a randomized, placebo-controlled, double-blinded, parallel dose-response study. Subjects: Healthy young adults (18-40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18-40 years)) completed the study. Intervention: The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 10 8 , 10 9 , 10 10 or 10 11 CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention. Results: The fecal recovery of BB-12 increased significantly (Po0.001) with increasing dose. In the group receiving 10 11 CFU/ day BB-12 was recovered from 13 out of 15 volunteers. CRL-431 was not recovered in any of the fecal samples. Supplementation with probiotics did not change the fecal bacterial composition. A significant linear increase in fecal consistency (looser stool) with increasing probiotic dose (P ¼ 0.018) was observed. No overall dose-response effect was found on the blood lipids. High doses of probiotics were well tolerated. Conclusion: A dose-related recovery of BB-12 from feces was observed. Sponsorship: The study was sponsored by Chr. Hansen A/S, Hoersholm, Denmark. Keywords: dose-response study; probiotics; cholesterol; recovery from feces; constipation European Journal of Clinical Nutrition IntroductionIt is generally accepted that the composition of the intestinal microflora influences the health and well being of humans. With the many publications showing beneficial effects of probiotic bacteria, there has been an increasing interest in the mechanism behind. Most clinical studies have tested only one dose of probiotics, ranging from 4 Â 10 8 CFU/day for determination of gastrointestinal colonization and immune modulation (Valeur et al., 2004) Contributors: DCE, CNL and KFM wrote the protocol. DCE performed the study. CNL did the microbiological analysis of fecal samples and study product. EB performed the fluorescent whole cell hybridization of BB-12 like colonies. MB performed the PFGE of CRL-431 like colonies. PK performed the statistical analysis. CNL and SN wrote the first draft of the paper and all contributors participated in the revision and final approval of the paper.

show abstract

Section: Introductionmentioning

confidence: 99%

Dose–response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults

Larsen

Nielsen²,

Kæstel³

et al. 2006

Eur J Clin Nutr

109

View full text Add to dashboard Cite

show abstract

“…The genera Bifidobacterium and Lactobacillus constitute a significant proportion of the probiotic cultures used in the food industry (15,24,25). The utilization of strains belonging to Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium bifidum, and Bifidobacterium infantis as probiotic starter cultures is due to their important role played in the large intestine, namely, control of the pH value and reduction of growth of many potential pathogens and putrefactive bacteria (4,8,19).…”

mentioning

confidence: 99%

Specific Identification and Targeted Characterization of Bifidobacterium lactis from Different Environmental Isolates by a Combined Multiplex-PCR Approach

Ventura

Reniero

Zink

2001

Appl Environ Microbiol

141

104

View full text Add to dashboard Cite

The species Bifidobacterium lactis, with its main representative strain Bb12 (DSM 10140), is a yoghurt isolate used as a probiotic strain and is commercially applied in different types of yoghurts and infant formulas. In order to ensure the genetic identity and safety of this bacterial isolate, species-and strain-specific molecular tools for genetic fingerprinting must be available to identify isolated bifidobacteria or lactic acid bacteria from, e.g., various clinical environments of relevance in medical microbiology. Two opposing rRNA gene-targeted primers have been developed for specific detection of this microorganism by PCR. The specificity of this approach was evaluated and verified with DNA samples isolated from single and mixed cultures of bifidobacteria and lactobacilli (48 isolates, including the type strains of 29 Bifidobacterium and 9 Lactobacillus species). Furthermore, we performed a Multiplex-PCR using oligonucleotide primers targeting a specific region of the 16S rRNA gene for the genus Bifidobacterium and a conserved eubacterial 16S rDNA sequence. The specificity and sensitivity of this detection with a pure culture of B. lactis were, respectively, 100 bacteria/ml after 25 cycles of PCR and 1 to 10 bacteria/ml after a 50-cycle nested-PCR approach.

show abstract

“…Этот штамм продуцирует антибиотикоподобные субстанции, совместим с инди-генной бифидофлорой, усиливает в биотопе синтез секреторных IgA-антител. B. lactis BB-12 имеет статус GRAS (Generally Regarded as Safe), означающий между-народное признание его безопасности и разрешающий неограниченное использование в пищевой и фармацев-тической промышленностях, а также безопасное приме-нение у детей с первых дней жизни [13,14]. По данным Комитета по питанию европейского общества детской гастроэнтерологии, гепатологии и питания (European Society of Paediatric Gastroenterology, Hepatology and Nutrition, ESPGHAN), применение пробиотиков в неона-тологии и раннем детском возрасте имеет 3 важных преимущества [15]: профиль эффективности и безопасности пробиотиков • делает их привлекательной альтернативой большому числу других, более агрессивных терапевтических подходов; применение пробиотиков является простым неинва-• зивным методом воссоздания нормальной микрофло-ры естественным путем с использованием природных механизмов; пробиотики эффективны для профилактики некроти-• ческого энтероколита -одного из наиболее опасных источников тяжелых осложнений у детей с низкой массой тела при рождении.…”

Section: Discussionunclassified

Experience of Adapted Probiotic Milk Formulas in Feeding of Infants of the 1st Year of Life

Эйберман¹,

Спиваковский²,

Быцкевич³

et al. 2013

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

ВВЕДЕНИЕ Не вызывает сомнений, что «золотым стандартом» вскармливания детей первого года жизни является грудное молоко, которое обеспечивает не только адек-ватное физическое развитие младенца, но и долго-срочный эффект профилактики ряда патологических состояний [1].К сожалению, питание детей первого года жизни во многих регионах Российской Федерации далеко от идеала и имеет значительное число недостатков

show abstract

Effect of Long Term Consumption of Infant Formulas With Bifidobacteria (B) and S. Thermophilus (St) on Stool Patterns and Diaper Rash in Infants

Cited by 17 publications

References 0 publications

Dose–response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults

Dose–response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults

Specific Identification and Targeted Characterization of Bifidobacterium lactis from Different Environmental Isolates by a Combined Multiplex-PCR Approach

Experience of Adapted Probiotic Milk Formulas in Feeding of Infants of the 1st Year of Life

Contact Info

Product

Resources

About